Vascular endothelial growth factor

The Cytokine Handbook

Volumn , Issue , 2003, Pages 1017-1034

  Gabrilovich, Dmitry I ^a   Dikov, Mikhail M ^b  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b VANDERBILT UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77954423057     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012689663-3/50048-X     Document Type: Chapter

References (194)

1. Abramson S., Miller R.G., Phillips R.A. The identification in adult bone marrow of pluripotent and restricted stem cells of the myeloid and lymphoid systems. J. Exp. Med. 1977, 145:1567-1579.
2. Achen M.G., Jeltsch M., Kukk E., et al. Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). Proc. Natl Acad. Sci. USA 1998, 95:548-553.
3. Adamis A.P., Miller J.W., Bernal M.T., et al. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am. J. Ophthalmol. 1994, 118:445-450.
4. Ahmed A., Dunk C., Kniss D., Wilkes M. Role of VEGF receptor-1 (Flt-1) in mediating calcium-dependent nitric oxide release and limiting DNA synthesis in human trophoblast cells. Lab. Invest. 1997, 76:779-791.
5. Almand B., Resser J.R., Lindman B., et al. Clin. Cancer Res. 2000, 6:1755-1766.
6. Alon T., Hemo I., Itin A., et al. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implication for retinopathy of prematurity. Nat. Med. 1995, 1:1024-1028.
7. Aprelikova O., Pajusola K., Partanen J., et al. FLT4, a novel class III receptor tyrosine kinase in chromosome 5q33-qter. Cancer Res. 1992, 52:746-748.
8. Banai S., Shweiki D., Pinson A., et al. Upregulation of vascular endothelial growth factor expression induced by myocardial ischemia: implication for coronary angigenesis. Cardiovasc. Res. 1994, 28:1176-1179.
9. Barleon B., Sozzani S., Zhou D., et al. Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood 1996, 87:3336-3343.
10. Baumgartner I., Pieczek A., Manor O., et al. Constitutive expression of phVEGF165 after intramascular gene transfer promotes collateral vessel development in patients with critical limb ischemia. Circulation 1998, 97:1114-1123.
11. Bellamy W., Richter L., Frutiger Y., Grogan T.M. Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies. Cancer Res. 1999, 59:728-733.
12. Bellamy W.T., Richter L., Sirjani D., et al. Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes. Blood 2001, 97:1427-1434.
13. Bellomo D., Headrick J.P., Silins G.U., et al. Mice lacking the vascular endothelial growth factor-B gene (Vegfb) have smaller hearts, dysfunctional coronary vasculature, and impaired recovery from cardiac ischemia. Circ. Res. 2000, 86:E29-E35.
14. Boehmelt G., Madruga J., Dorfler P., et al. Dendritic cell progenitor is transformed by a conditional v-rel estrogen receptor fusion protein v-RelER. Cell 1995, 80:341-352.
15. Broxmeyer H.E., Cooper S., Li Z.H., et al. Myeloid progenitor cells regulatory effects of vascular endothelial cell growth factor. Int. J. Hematol. 1995, 62:203-215.
16. Broxmeyer H.E., Cooper S., Li Z.-H., et al. Macrophage-stimulating protein, a ligand for the RON receptor protein tyrosine kinase, suppress myeloid progenitor cell proliferation and synergizes with vascular endothelial growth factor and members of the chemokine family. Ann. Hematol. 1996, 73:1-9.
17. Burkly L., Hession C., Ogata L., et al. Expression of RelB is required for development of thymic medulla and dendritic cells. Nature 1995, 373:531-536.
18. Cao Y., Chen H., Zhou L., et al. Heterodimers of placenta growth factor/vascular endothelial growth factor. Endothelial activity, tumor cell expression, and high affinity binding to Flk-1/KDR. J. Biol. Chem. 1996, 271:3154-3162.
19. Carmeliet P., Ferreira V., Breier G., et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 1996, 380:435-439.
20. Carmeliet P., Moons L., Luttun A., et al. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat. Med. 2001, 7:575-583.
21. Carrasco D., Ryseck R.-P., Bravo R. Expression of relB transcripts during lymphoid organ development: specific expression in dendritic antigen-presenting cells. Development 1993, 118:1221-1231.
22. Chilov D., Kukk E., Taira S., et al. Genomic organization of human and mouse genes for vascular endothelial growth factor C. J. Biol. Chem. 1997, 272:25176-25183.
23. Choi K., Wall C., Hanratty R., Keller G. Isolation of a gene encoding a novel receptor tyrosine kinase from differentiated embryonic stem cells. Oncogene 1994, 9:1261-1266.
24. Claffey K.P., Senger D.R., Spiegelman B.M. Structural requirements for dimerization, glycosylation, secretion, and biological function of VPF/VEGF. Biochim. Biophys. Acta 1995, 1246:1-9.
25. Clauss M., Weich H., Breier G., et al. The vascular endothelial growth factor receptor Flt-1 mediates biological activities. J. Biol. Chem. 1996, 271:17629-17634.
26. Clauss M., Weich H., Breier G., et al. The vascular endothelial growth factor receptor Flt-1 mediates biological activities. Implications for a functional role of placenta growth factor in monocyte activation and chemotaxis. J. Biol. Chem. 1996, 271:17629-17634.
27. Cohen T., Gitay-Goren H., Sharon R., et al. VEGF121, a vascular endothelial growth factor (VEGF) isoform lacking heparin binding ability, requires cell-surface heparan sulfates for efficient binding to the VEGF receptors of human melanoma cells. J. Biol. Chem. 1995, 270:11322-11326.
28. Cross M.J., Claesson-Welsh L. FGF and VEGF function in angiogenesis: signalling pathways, biological responses, and therapeutic inhibition. Trends Pharmacol. Sci. 2001, 22:201-207.
29. Cunningham S.A., Waxham M.N., Arrate P.M., Brock T.A. Interaction of the Flt-1 tyrosine kinase receptor with the p85 subunit of phosphatidylinositol 3-kinase. Mapping of a novel site involved in binding. J. Biol. Chem. 1995, 270:20254-20257.
30. Cunningham S.A., Tran T.M., Arrate M.P., Brock T.A. Characterization of vascular endothelial cell growth factor interactions with the kinase insert domain-containing receptor tyrosine kinase. A real time kinetic study. J. Biol. Chem. 1999, 274:18421-18427.
31. de Vries C., Escobedo J.A., Ueno H., et al. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 1992, 255:989-991.
32. Dias S., Hattori K., Zhu Z., et al. Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration. J. Clin. Invest. 2000, 106:511-521.
33. Dikov M.M., Oyama T., Cheng P., et al. Vascular endothelial growth factor effects on nuclear factor-kappaB activation in hematopoietic progenitor cells. Cancer Res. 2001, 61:2015-2021.
34. DiSalvo J., Bayne M.L., Conn G., et al. Purification and characterization of a naturally occurring vascular endothelial growth factor placenta growth factor heterodimer. J. Biol. Chem. 1995, 270:7717-7723.
35. Dougher-Vermazen M., Hulmes J.D., Bohlen P., Terman B.I. Biological activity and phosphorylation sites of the bacterially expressed cytosolic domain of the KDR VEGF-receptor. Biochem. Biophys. Res. Commun. 1994, 205:728-738.
36. Dumont D.J., Jussila L., Taipale J., et al. Cardiovascular failure in mouse embryos deficient in VEGF receptor-3. Science 1998, 282:946-949.
37. Dunk C., Ahmed A. Vascular endothelial growth factor receptor-2-mediated mitogenesis is negatively regulated by vascular endothelial growth factor receptor-1 in tumor epithelial cells. Am. J. Pathol. 2001, 158:265-273.
38. Dvorak H.F., Detmar M., Claffey K.P., et al. Vascular permeability factor/vascular endothelial growth factor: an important mediator of angiogenesis in malignancy and inflammation. Int. Arch. Allerg. Immunol. 1995, 107:233-235.
39. Eglitis M.A., Kantoff P., Gilboa E., Anderson W.F. Gene expression in mice after high efficiency retroviral-mediated gene transfer. Science 1985, 230:1395.
40. Ellis L.M., Fidler I.J. Angiogenesis and metastasis. Eur. J. Cancer 1996, 32A:2451-2460.
41. Fairbrother W.J., Champe M.A., Christinger H.W., et al. Solution structure of the heparin-binding domain of vascular endothelial growth factor. Structure 1998, 6:637-648.
42. Ferrara N., Smyth D.T. The biology of vascular endothelial growth factor. Endocrine Rev. 1997, 18:4-25.
43. Ferrara N., Houck K., Jakeman L., Leung D.W. Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endocrine Rev. 1992, 13:18-32.
44. Ferrara N., Carver-Moore K., Chen H., et al. Heterozygous embryoniclethality induced be targeted inactivation of the VEGF gene. Nature 1996, 380:439-442.
45. Ferrara N., Chen H., Davis-Smyth T., et al. Vascular endothelial growth factor is essential for corpus luteum angiogenesis. Nat. Med. 1998, 4:336-340.
46. Fiedler W., Graeven U., Ergun S., et al. Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia. Blood 1997, 89:1870-1875.
47. Finnerty H., Kelleher K., Morris G.E., et al. Molecular cloning of murine FLT and FLT4. Oncogene 1993, 8:2293-2298.
48. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other diseases. Nat. Med. 1995, 1:27-31.
49. Fong G.H., Rossant J., Gertsenstein M., Breitman M.L. Role of Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 1995, 376:66-70.
50. Fong G.H., Zhang L., Bryce D.M., Peng J. Increased hemangioblast commitment, not vascular disorganization, is the primary defect in flt-1 knock-out mice. Development 1999, 126:3015-3025.
51. Forsythe J.A., Jiang B.H., Iyer N.V., et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol. Cell. Biol. 1996, 16:4604-4613.
52. Gabrilovich D., Girgis K., Cunningham H., et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat. Med. 1996, 2:1096.
53. Gabrilovich D.I., Ishida T., Oyama T., et al. Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood 1998, 92:4150-4166.
54. Gabrilovich D.I., Ishida T., Nadaf S., et al. Clin. Cancer Res. 1999, 5:2963-2970.
55. Galland F., Karamysheva A., Mattei M.G., et al. Chromosomal localization of FLT4, a novel receptor-type tyrosine kinase gene. Genomics 1992, 13:475-478.
56. Gerber H.P., Dixit V., Ferrara N. Vascular endothelial growth factor induces expression of the antiapoptotic proteins Bcl-2 and A1 in vascular endothelial cells. J. Biol. Chem. 1998, 273:13313-13316.
57. Gerber H.P., McMurtrey A., Kowalski J., et al. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J. Biol. Chem. 1998, 273:30336-30343.
58. Gerber H.P., Hillan K.J., Ryan A.M., et al. VEGF is required for growth and survival in neonatal mice. Development 1999, 126:1149-1159.
59. Gerber H.P., Vu T.H., Ryan A.M., et al. VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation. Nat. Med. 1999, 5:623-628.
60. Gille H., Kowalski J., Yu L., et al. A repressor sequence in the juxtamembrane domain of Flt-1 (VEGFR-1) constitutively inhibits vascular endothelial growth factor-dependent phosphatidylinositol 3'-kinase activation and endothelial cell migration. EMBO J. 2000, 19:4064-4073.
61. Grimmond S., Lagercrantz J., Drinkwater C., et al. Cloning and characterization of a novel human gene related to vascular endothelial growth factor. Genome Res. 1996, 6:124-131.
62. Gruber B.L., Marchese M.J., Kew R. Angiogenic factors stimulate mast-cell migration. Blood 1995, 86:2488.
63. Guo D., Jia Q., Song H.Y., et al. Vascular endothelial cell growth factor promotes tyrosine phosphorylation of mediators of signal transduction that contain SH2 domains. Association with endothelial cell proliferation. J. Biol. Chem. 1995, 270:6729-6733.
64. Haig D.M., Mercer A.A. Ovine diseases. Orf. Vet. Res. 1998, 29:311-326.
65. Hauser S., Weich H.A. A heparin-binding form of placenta growth factor (PlGF-2) is expressed in human umbilical vein endothelial cells and in placenta. Growth Factors 1993, 9:259-268.
66. He H., Venema V.J., Gu X., et al. Vascular endothelial growth factor signals endothelial cell production of nitric oxide and prostacyclin through flk-1/KDR activation of c-Src. J. Biol. Chem. 1999, 274:25130-25135.
67. Heldin C.H., Ostman A., Westermark B. Structure of platelet-derived growth factor: implications for functional properties. Growth Factors 1993, 8:245-252.
68. Henry T.D. Therapeutic angiogenesis. Br. Med. J. 1999, 318:1536-1539.
69. Hiratsuka S., Minowa O., Kuno J., et al. Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice. Proc. Natl Acad. Sci. USA 1998, 95:9349-9354.
70. Hoehn G.T., Stokland T., Amin S., et al. Tnkl: a novel intracellular tyrosine kinase gene isolated from human umbilical cord blood CD34+/Lin-/CD38- stem/progenitor cells. Oncogene 1996, 12:903-913.
71. Houck K.A., Ferrara N., Winer J., et al. The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA. Mol. Endocrinol. 1991, 5:1806-1814.
72. Huang K., Andersson C., Roomans G.M., et al. Signaling properties of VEGF receptor-1 and -2 homo- and heterodimers. Int. J. Biochem. Cell. Biol. 2001, 33:315-324.
73. Huang L., Sankar S., Lin C., et al. HCPTPA, a protein tyrosine phosphatase that regulates vascular endothelial growth factor receptor-mediated signal transduction and biological activity. J. Biol. Chem. 1999, 274:38183-38188.
74. Igarashi K., Isohara T., Kato T., et al. Tyrosine 1213 of Flt-1 is a major binding site of Nck and SHP-2. Biochem. Biophys. Res. Commun. 1998, 246:95-99.
75. Isaji M., Miyata H., Ajisawa Y., et al. Tranilast inhibits the proliferation, chemotaxis and tube formation of human microvascular endothelial cells in vitro and angiogenesis in vivo. Br. J. Pharmacol. 1997, 122:1061.
76. Ishida T., Oyama T., Carbone D., Gabrilovich D.I. Defective function of Langerhans cells in tumor-bearing animals is the result of defective maturation from hematopoietic progenitors. J. Immunol. 1998, 161:4842-4851.
77. Jeltsch M., Kaipainen A., Joukov V., et al. Hyperplasia of lymphatic vessels in VEGF-C transgenic mice. Science 1997, 276:1423-1425.
78. Joukov V., Pajusola K., Kaipainen A., et al. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J. 1996, 15:290-298.
79. Joukov V., Sorsa T., Kumar V., et al. Proteolytic processing regulates receptor specificity and activity of VEGF-C. EMBO J. 1997, 16:3898-3911.
80. Joukov V., Kumar V., Sorsa T., et al. A recombinant mutant vascular endothelial growth factor-C that has lost vascular endothelial growth factor receptor-2 binding, activation, and vascular permeability activities. J. Biol. Chem. 1998, 273:6599-6602.
81. Kanno S., Oda N., Abe M., et al. Roles of two VEGF receptors, Flt-1 and KDR, in the signal transduction of VEGF effects in human vascular endothelial cells. Oncogene 2000, 19:2138-2146.
82. Katoh O., Tauchi H., Kawaishi K., et al. Expression of the vascular endothelial growth factor (VEGF) receptor gene, KDR, in hematopoetic cells and inhibitory effect of VEGF on apoptotic cell death caused by ionizing radiation. Cancer Res. 1995, 55:5687-5692.
83. Kawasaki T., Kitsukawa T., Bekku Y., et al. A requirement for neuropilin-1 in embryonic vessel formation. Development 1999, 126:4895-4902.
84. Keck P.J., Hauser S.D., Krivi G., et al. Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science 1989, 246:1309-1312.
85. Kendall R.L., Thomas K.A. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc. Natl. Acad. Sci. USA 1993, 90:10705-10709.
86. Kennedy M., Firpo M., Choi K., et al. A common precursor for primitive erythropoiesis and definitive haematopoiesis. Nature 1997, 386:488-493.
87. Keyt B.A., Nguyen H.V., Berleau L.T., et al. Identification of vascular endothelial growth factor determinants for binding KDR and FLT-1 receptors. Generation of receptor-selective VEGF variants by site-directed mutagenesis. J. Biol. Chem. 1996, 271:5638-5646.
88. Kitsukawa T., Shimizu M., Sanbo M., et al. Neuropilin-semaphorin III/D-mediated chemorepulsive signals play a crucial role in peripheral nerve projection in mice. Neuron 1997, 19:995-1005.
89. Kondo S., Asano M., Matsuo K., et al. Vascular endothelial growth factor/vascular permeability factor is detectable in the sera of tumor-bearing mice and cancer patients. Bioch. Biophys. Acta 1994, 1221:211-214.
90. Kondo K., Hiratsuka S., Subbalakshmi E., et al. Genomic organization of the flt-1 gene encoding for vascular endothelial growth factor (VEGF) receptor-1 suggests an intimate evolutionary relationship between the 7-Ig and the 5-Ig tyrosine kinase receptors. Gene 1998, 208:297-305.
91. Korpelainen E.I., Karkkainen M., Gunji Y., et al. Endothelial receptor tyrosine kinases activate the STAT signaling pathway: mutant Tie-2 causing venous malformations signals a distinct STAT activation response. Oncogene 1999, 18:1-8.
92. Kroll J., Waltenberger J. The vascular endothelial growth factor receptor KDR activates multiple signal transduction pathways in porcine aortic endothelial cells. J. Biol. Chem. 1997, 272:32521-32527.
93. Kroll J., Waltenberger J. A novel function of VEGF receptor-2 (KDR): rapid release of nitric oxide in response to VEGF-A stimulation in endothelial cells. Biochem. Biophys. Res. Commun. 1999, 265:636-639.
94. Kukk E., Lymboussaki A., Taira S., et al. VEGF-C receptor binding and pattern of expression with VEGFR-3 suggests a role in lymphatic vascular development. Development 1996, 122:3829-3837.
95. Kupferminc M.J., Daniel Y., Englender T., et al. Vascular endothelial growth factor is increased in patients with preeclampsia. Am. J. Reprod. Immunol. 1997, 38:302-306.
96. Landgren E., Schiller P., Cao Y., Claesson-Welsh L. Placenta growth factor stimulates MAP kinase and mitogenicity but not phospholipase C-gamma and migration of endothelial cells expressing Flt 1. Oncogene 1998, 16:359-367.
97. Lee J., Gray A., Yuan J., et al. Vascular endothelial growth factor-related protein: a ligand and specific activator of the tyrosine kinase receptor Flt4. Proc. Natl Acad. Sci. USA 1996, 93:1988-1992.
98. Leung D.W., Cachianes G., Kuang W.J., et al. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989, 246:1306-1309.
99. Leung D.W., Cachianes G., Kuang W.-J., et al. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989, 246:1306-1309.
100. Levy A.P., Levy N.S., Wegner S., Goldberg M.A. Transcriptional regulation of the rat vascular endothelial growth factor gene by hypoxia. J. Biol. Chem. 1995, 270:13333-13340.
101. Li X., Eriksson U. Novel VEGF family members: VEGF-B, VEGF-C and VEGF-D. Int. J. Biochem. Cell. Biol. 2001, 33:421-426.
102. Liou H.-C., Baltimore D. Regulation of the NF-kB/rel transcription factor and IkB inhibitor system. Curr. Opin. Cell. Biol. 1993, 5:477-487.
103. Liu Y., Cox S.R., Morita T., Kourembanas S. Hypoxia regulates vascular endothelial growth factor gene expression in endothelial cells. Identification of a 5' enhancer. Circ. Res. 1995, 77:638-643.
104. Lyttle D.J., Fraser K.M., Fleming S.B., et al. Homologs of vascular endothelial growth factor are encoded by the poxvirus orf virus. J. Virol. 1994, 68:84-92.
105. Madan A., Curtin P.T. A 24-base-pair sequence 3' to the human erythropoietin gene contains a hypoxia-responsive transcriptional enhancer. Proc. Natl Acad. Sci. USA 1993, 90:3928-3932.
106. Maglione D., Guerriero V., Viglietto G., et al. Two alternative mRNAs coding for the angiogenic factor, placenta growth factor (PIGF), are transcribed from a single gene of chromosome 14. Oncogene 1993, 8:925-931.
107. Mattei M.G., Borg J.P., Rosner O., et al. Assignment of vascular endothelial growth factor (VEGF) and placenta growth factor (PLGF) genes to human chromosome 6p12-p21 and 14q24-q31 regions, respectively. Genomics 1996, 32:168-169.
108. Matthews W., Jordan C.T., Gavin M., et al. A receptor tyrosine kinase cDNA isolated from a population of enriched primitive hematopoietic cells and exhibiting close genetic linkage to c-kit. Proc. Natl Acad. Sci. USA 1991, 88:9026-9030.
109. McDonald N.Q., Hendrickson W.A. A structural superfamily of growth factors containing a cystine knot motif. Cell 1993, 73:421-424.
110. Meyer M., Clauss M., Lepple-Wienhues A., et al. A novel vascular endothelial growth factor encoded by Orf virus, VEGF-E, mediates angiogenesis via signalling through VEGFR-2 (KDR) but not VEGFR-1 (Flt-1) receptor tyrosine kinase. EMBO J. 1999, 18:363-374.
111. Migdal M., Huppertz B., Tessler S., et al. Neuropilin-1 is a placenta growth factor-2 receptor. J. Biol. Chem. 1998, 273:22272-22278.
112. Mintz B., Anthony K., Litwin S. Monoclonal derivation of mouse myeloid and lymphoid lineages from totipotent hematopoietic stem cells experimentally engrafted in fetal hosts. Proc. Natl Acad. Sci. USA 1984, 81:7835-7839.
113. Molinex G., Schofield R., Testa N.G. Development of spleen CFU-S colonies from day 8 to day 11. Exp. Hematol. 1986, 14:710-713.
114. Muller Y.A., Christinger H.W., Keyt B.A., de Vos A.M. The crystal structure of vascular endothelial growth factor (VEGF) refined to 1.93 A resolution: multiple copy flexibility and receptor binding. Structure 1997, 5:1325-1338.
115. Murray-Rust J., McDonald N.Q., Blundell T.L., et al. Topological similarities in TGF-beta 2, PDGF-BB and NGF define a superfamily of polypeptide growth factors. Structure 1993, 1:153-159.
116. Nakahata T., Ogawa M. Identification in culture of a new class of hemopoietic colony-forming units with extensive capability of self-renew and generate multipotential hemopoietic colonies. Proc. Natl Acad. Sci. USA 1982, 79:3843-3847.
117. Neufeld G., Cohen T., Gitay-Goren H., et al. Similarities and differences between the vascular endothelial growth factor (VEGF) splice variants. Cancer Metastasis Rev. 1996, 15:153-158.
118. Neufeld G., Cohen T., Gengrinovitch S., Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. Faseb J. 1999, 13:9-22.
119. Nishikawa S.I., Nishikawa S., Hirashima M., et al. Progressive lineage analysis by cell sorting and culture identifies FLK1+VE-cadherin+ cells at a diverging point of endothelial and hemopoietic lineages. Development 1998, 125:1747-1757.
120. Ogawa S., Oku A., Sawano A., et al. A novel type of vascular endothelial growth factor, VEGF-E (NZ-7 VEGF), preferentially utilizes KDR/Flk-1 receptor and carries a potent mitotic activity without heparin-binding domain. J. Biol. Chem. 1998, 273:31273-31282.
121. Ohm J.E., Shurin M.R., Esche C., et al. J. Immunol. 1999, 163:3260-3268.
122. Olofsson B., Pajusola K., von Euler G., et al. Genomic organization of the mouse and human genes for vascular endothelial growth factor B (VEGF-B) and characterization of a second splice isoform. J. Biol. Chem. 1996, 271:19310-19317.
123. Olofsson B., Korpelainen E., Pepper M.S., et al. Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells. Proc. Natl Acad. Sci. USA 1998, 95:11709-11714.
124. B.Olofsson, Jeltsch M., Eriksson U., Alitalo K. Current biology of VEGF-B and VEGF-C. Curr. Opin. Biotechnol. 1999, 10:528-535.
125. Ortega N., L'Faqihi E.E., Plouet J. Control of vascular endothelial growth factor angiogenic activity by the extracellular matrix. Biol. Cell. 1998, 90:381-390.
126. Oyama T., Ran S., Ishida T., et al. Vascular endothelial growth factor affects dendritic cell maturation through the inhibition of nuclear factor-kappaB activation in hemopoietic progenitor cells. J. Immunol. 1998, 160:1224.
127. Oyama T., Ran S., Ishida T., et al. Vascular endothelial growth factor affects dendritic cell maturation through the inhibition of nuclear factor-kB activation in hematopoietic progenitor cells. J. Immunol. 1998, 160:1224-1232.
128. Paavonen K., Horelli-Kuitunen N., Chilov D., et al. Novel human vascular endothelial growth factor genes VEGF-B and VEGF-C localize to chromosomes 11q13 and 4q34, respectively. Circulation 1996, 93:1079-1082.
129. Park J.E., Chen H.H., Winer J., et al. Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, an DR. J. Biol. Chem. 1994, 269:25646-25654.
130. Partanen T.A., Makinen T., Arola J., et al. Endothelial growth factor receptors in human fetal heart. Circulation 1999, 100:583-586.
131. Peretz D., Gitay-Goren H., Safran M., et al. Glycosylation of vascular endothelial growth factor is not required for its mitogenic activity. Biochem. Biophys. Res. Commun. 1992, 182:1340-1347.
132. Petrova T.V., Makinen T., Alitalo K. Signaling via vascular endothelial growth factor receptors. Exp. Cell. Res. 1999, 253:117-130.
133. Plouet J., Moro F., Bertagnolli S., et al. Extracellular cleavage of the vascular endothelial growth factor 189-amino acid form by urokinase is required for its mitogenic effect. J. Biol. Chem. 1997, 272:13390-13396.
134. Poltorak Z., Cohen T., Sivan R., et al. VEGF145, a secreted vascular endothelial growth factor isoform that binds to extracellular matrix. J. Biol. Chem. 1997, 272:7151-7158.
135. Rahimi N., Dayanir V., Lashkari K. Receptor chimeras indicate that the vascular endothelial growth factor receptor-1 (VEGFR-1) modulates mitogenic activity of VEGFR-2 in endothelial cells. J. Biol. Chem. 2000, 275:16986-16992.
136. Robinson C.J., Stringer S.E. The splice variants of vascular endothelial growth factor (VEGF) and their receptors. J. Cell. Sci. 2001, 114:853-865.
137. Roeckl W., Hecht D., Sztajer H., et al. Differential binding characteristics and cellular inhibition by soluble VEGF receptors 1 and 2. Exp. Cell. Res. 1998, 241:161-170.
138. Rosnet O., Schiff C., Pebusque M.J., et al. Human FLT3/FLK2 gene: cDNA cloning and expression in hematopoietic cells. Blood 1993, 82:1110-1119.
139. Rosnet O., Stephenson D., Mattei M.G., et al. Close physical linkage of the FLT1 and FLT3 genes on chromosome 13 in man and chromosome 5 in mouse. Oncogene 1993, 8:173-179.
140. Saito H., Tsujitani S., Ikeguchi M., et al. Relationship between the expression of vascular endothelial growth factor and the density of dendritic cells in gastric adenocarcinoma tissue. Br. J. Cancer 1998, 78:1573-1577.
141. Sato Y., Abe M., Tanaka K., et al. Signal transduction and transcriptional regulation of angiogenesis. Adv. Exp. Med. Biol. 2000, 476:109-115.
142. Sato Y., Kanno S., Oda N., et al. Properties of two VEGF receptors, Flt-1 and KDR, in signal transduction. Ann. NY Acad. Sci. 2000, 902:201-205. discussion 205-207.
143. Sawano A., Takahashi T., Yamaguchi S., et al. Flt-1 but not KDR/Flk-1 tyrosine kinase is a receptor for placenta growth factor, which is related to vascular endothelial growth factor. Cell Growth Diff. 1996, 7:213-221.
144. Sawano A., Takahashi T., Yamaguchi S., Shibuya M. The phosphorylated 1169-tyrosine containing region of flt-1 kinase (VEGFR-1) is a major binding site for PLCgamma. Biochem. Biophys. Res. Commun. 1997, 238:487-491.
145. Sawano A., Iwai S., Sakurai Y., et al. Flt-1, vascular endothelial growth factor receptor 1, is a novel cell surface marker for the lineage of monocyte-macrophages in humans. Blood 2001, 97:785-791.
146. Seetharam L., Gotoh N., Maru Y., et al. A unique signal transduction from FLT tyrosine kinase, a receptor for vascular endothelial growth factor VEGF. Oncogene 1995, 10:135-147.
147. Senger D., Connolly D., Van de Water L., et al. Purification and NH2-terminal amino acid sequence of guinea pig tumor-secreted vascular permeability factor. Cancer Res. 1990, 50:1774-1778.
148. Senger D.R., van de Water L., Brown L.F., et al. Vascular permeability factor (VPF/VEGF) in tumor biology. Cancer Metastasis Rev. 1993, 12:303.
149. Shalaby F., Rossant J., Yamaguchi T.P., et al. Failure of blood island formation and vascularogenesis in Flk-1-deficient mice. Nature 1995, 376:62-66.
150. Shen B.Q., Lee D.Y., Zioncheck T.F. Vascular endothelial growth factor governs endothelial nitric-oxide synthase expression via a KDR/Flk-1 receptor and a protein kinase C signaling pathway. J. Biol. Chem. 1999, 274:33057-33063.
151. Shibuya M. Structure and dual function of vascular endothelial growth factor receptor-1 (Flt-1). Int. J. Biochem. Cell. Biol. 2001, 33:409-420.
152. Shibuya M. Structure and function of VEGF/VEGF-receptor system involved in angiogenesis. Cell. Struct. Funct. 2001, 26:25-35.
153. Shibuya M., Yamaguchi S., Yamane A., et al. Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to the fms family. Oncogene 1990, 5:519-524.
154. Shibuya M., Ito N., Claesson-Welsh L. Structure and function of vascular endothelial growth factor receptor-1 and -2. Curr. Top. Microbiol. Immunol. 1999, 237:59-83.
155. Shima D.T., Adamis A.P., Ferrara N.P., et al. Hypoxic induction of vascular endothelial cell growth factors in the retina: identification and characterization of vascular endothelial growth factor (VEGF) as the sole mitogen. Mol. Med. 1995, 2:64-71.
156. Shweiki D., Itin A., Soffer D., Keshet E. Vascular endothelial gowth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992, 359:843-845.
157. Siemeister G., Schirner M., Reusch P., et al. An antagonistic vascular endothelial growth factor (VEGF) variant inhibits VEGF-stimulated receptor autophosphorylation and proliferation of human endothelial cells. Proc. Natl Acad. Sci. USA 1998, 95:4625-4629.
158. Soker S., Takashima S., Miao H.Q., et al. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 1998, 92:735-745.
159. Songyang Z., Shoelson S.E., Chaudhuri M., et al. SH2 domains recognize specific phosphopeptide sequences. Cell 1993, 72:767-778.
160. Spritz R.A., Strunk K.M., Lee S.T., et al. A YAC contig spanning a cluster of human type III receptor protein tyrosine kinase genes (PDGFRA-KIT-KDR) in chromosome segment 4q12. Genomics 1994, 22:431-436.
161. Sun P.D., Davies D.R. The cystine-knot growth-factor superfamily. Annu. Rev. Biophys. Biomol. Struct. 1995, 24:269-291.
162. Suzuma K., Naruse K., Suzuma I., et al. Vascular endothelial growth factor induces expression of connective tissue growth factor via KDR, Flt1, and phosphatidylinositol 3-kinase-akt-dependent pathways in retinal vascular cells. J. Biol. Chem. 2000, 275:40725-40731.
163. Takahashi T., Shibuya M. The 230 kDa mature form of KDR/Flk-1 (VEGF receptor-2) activates the PLC-gamma pathway and partially induces mitotic signals in NIH3T3 fibroblasts. Oncogene 1997, 14:2079-2089.
164. Takahashi T., Yamaguchi S., Chida K., Shibuya M. A single autophosphorylation site on KDR/Flk-1 is essential for VEGF-A-dependent activation of PLC-gamma and DNA synthesis in vascular endothelial cells. EMBO J. 2001, 20:2768-2778.
165. Takano S., Yoshii Y., Kondo S., et al. Concentration of vascular endothelial growth factor in the serum and tumor tissue of brain tumor patients. Cancer Res. 1996, 56:2185-2190.
166. Takeshita S., Zheng L.P., Brogi E., et al. Therapeutic angiogenesis. A single intraarterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hind limb model. J. Clin. Invest. 1994, 93:662-670.
167. Terman B.I., Carrion M.E., Kovacs E., et al. Identification of a new endothelial cell growth factor receptor tyrosine kinase. Oncogene 1991, 6:1677-1683.
168. Terman B.I., Dougher-Vermazen M., Carrion M.E., et al. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. Biochem. Biophys. Res. Commun. 1992, 187:1579-1586.
169. Terman B.I., Jani-Sait S., Carrion M.E., Shows T.B. The KDR gene maps to human chromosome 4q31.2-q32, a locus which is distinct from locations for other type III growth factor receptor tyrosine kinases. Cytogenet. Cell. Genet. 1992, 60:214-215.
170. Thanos D., Maniatis T. NF-kB-A lesson in family values. Cell 1995, 80:529-532.
171. Tischer E., Mitchell R., Hartman T., et al. The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J. Biol. Chem. 1991, 266:11947-11954.
172. Toi M., Taniguchi T., Yamamoto Y., et al. Clinical significance of the determination of angiogenic factors. (Review). Eur. J. Cancer 1996, 32A:2513-2519.
173. Torry D.S., Ahn H., Barnes E.L., Torry R.J. Placenta growth factor: potential role in pregnancy. Am. J. Reprod. Immunol. 1999, 41:79-85.
174. Townson S., Lagercrantz J., Grimmond S., et al. Characterization of the murine VEGF-related factor gene. Biochem. Biophys. Res. Commun. 1996, 220:922-928.
175. Tsukamoto A.S., Chen B.P., Hoffman R., et al. Phenotypic and functional analysis of hematopoietic stem cells in mouse and human. Hematopoietic Stem Cells 1995, 85-124. Marcel Dekker, New York. D. Levitt, R. Mertessmann (Eds.).
176. Tuder R.M., Flook B., Voelkel N.F. Increased gene expression for VEGF and the VEGF receptors KDR/Flk and Flt in lungs exposed to acute or to chronic hypoxia. Modulation of gene expression by nitric oxide. J. Clin. Invest. 1995, 95:1798-1807.
177. Van Zant G., Chen J.-J., Scott-Micus K. Developmental potential of hematopoietic stem cells determined using retrovirally marked allophenic marrow. Blood 1991, 77:756-763.
178. Veikkola T., Alitalo K. VEGFs, receptors and angiogenesis. Semin. Cancer Biol. 1999, 9:211-220.
179. Verma I.M., Stevenson J.K., Scharz E.M., et al. Rel/NF-kB/IkB family: intimate tales of association and dissociation. Genes Dev. 1995, 9:2723-2735.
180. Vincenti V., Cassano C., Rocchi M., Persico G. Assignment of the vascular endothelial growth factor gene to human chromosome 6p21.3. Circulation 1996, 93:1493-1495.
181. Vuorela P., Hatva E., Lymboussaki A., et al. Expression of vascular endothelial growth factor and placenta growth factor in human placenta. Biol. Reprod. 1997, 52:489-494.
182. Waltenberger J., Claesson-Welsh L., Siegbahn A., et al. Different signal transduction properties of KDR and Fltl, two receptors for vascular endothelial growth factor. J. Biol. Chem. 1994, 269:26988-26995.
183. Wang J.F., Ganju R.K., Liu Z.Y., et al. Signal transduction in human hematopoietic cells by vascular endothelial growth factor related protein, a novel ligand for the FLT4 receptor. Blood 1997, 90:3507-3515.
184. Watkins-Chow D.E., Douglas K.R., Buckwalter M.S., et al. Construction of a 3-Mb contig and partial transcript map of the central region of mouse chromosome 11. Genomics 1997, 45:147-157.
185. Wheeler-Jones C., Abu-Ghazaleh R., Cospedal R., et al. Vascular endothelial growth factor stimulates prostacyclin production and activation of cytosolic phospholipase A2 in endothelial cells via p42/p44 mitogen-activated protein kinase. FEBS Lett. 1997, 420:28-32.
186. Wiesmann C., Fuh G., Christinger H.W., et al. Cell 1997, 91:695-704.
187. Wu L., D'Amico A., Winkel K.D., et al. RelB is essential for the development of myeloid-related CD8 alpha (-) dendritic cells but not of lymphoid-related CD8 alpha (+) dendritic cells. Immunity 1998, 9:839-847.
188. Yamane A., Seetharam L., Yamaguchi S., et al. A new communication system between hepatocytes and sinusoidal endothelial cells in liver through vascular endothelial growth factor and Flt tyrosine kinase receptor family (Flt-1 and KDR/Flk-1). Oncogene 1994, 9:2683-2690.
189. Young M., Kolesiak K., Wright M., Gabrilovich D. Chemoattraction of femoral CD34+ progenitor cells by tumor-derived vascular endothelial cell growth factor. Clin. Exp. Metastasis 1999, 17:881.
190. Young M., Petruzelli G., Kolesiak K., et al. Human squamos cell carcinomas of the head and neck chemoattract immune suppressive CD34(+) progenitor cells. Hum. Immunol. 2001, 62:332.
191. Zachary I., Gliki G. Signaling transduction mechanisms mediating biological actions of the vascular endothelial growth factor family. Cardiovasc. Res. 2001, 49:568-581.
192. Zeng H., Dvorak H.F., Mukhopadhyay D. Vascular permeability factor (VPF)/vascular endothelial growth factor (VEGF) receptor-1 down-modulates VPF/VEGF receptor-2-mediated endothelial cell proliferation, but not migration, through phosphatidylinositol 3-kinase-dependent pathways. J. Biol. Chem. 2001, 276:26969-26979.
193. Ziche M., Maglione D., Ribatti D., et al. Placenta growth factor-1 is chemotactic, mitogenic, and angiogenic. Lab. Invest. 1997, 76:517-531.
194. Ziegler B.L., Valtieri M., Porada G.A., et al. KDR receptor: a key marker defining hematopoietic stem cells. Science 1999, 285:1553-1558.